Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

61. Reward-related ventral striatum activity links polygenic risk for attention-deficit/hyperactivity disorder to problematic alcohol use in young adulthood Full Text available with Trip Pro

Reward-related ventral striatum activity links polygenic risk for attention-deficit/hyperactivity disorder to problematic alcohol use in young adulthood Problematic alcohol use in adolescence and adulthood is a common and often debilitating correlate of childhood attention-deficit/hyperactivity disorder (ADHD). Converging evidence suggests that ADHD and problematic alcohol use share a common additive genetic basis, which may be mechanistically related to reward-related brain function (...) . In the current study, we examined whether polygenic risk for childhood ADHD is linked to problematic alcohol use in young adulthood through alterations in reward-related activity of the ventral striatum, a neural hub supporting appetitive behaviors and reinforcement learning.Genomic, neuroimaging, and self-report data were available for 404 non-Hispanic European-American participants who completed the ongoing Duke Neurogenetics Study. Polygenic risk scores for childhood ADHD were calculated based on a genome

2017 Biological psychiatry. Cognitive neuroscience and neuroimaging

62. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder

The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder Kim Boesen , Luis Carlos Saiz , Juan Erviti , Ole Jakob Storebø , Christian Gluud , Peter C Gøtzsche , Karsten Juhl Jørgensen Statistics from Altmetric.com Background Attention deficit hyperactivity disorder (ADHD) in adults is one of the most controversial diagnoses in medicine, and the use of methylphenidate is sharply rising. The Cochrane review by Epstein and colleagues about (...) The trials lasted only 1–7 weeks, and the long-term beneficial and harmful effects of methylphenidate are therefore unknown. Most adults with ADHD receive methylphenidate for substantially longer periods, and the beneficial effects may furthermore diminish over time. This was observed in the large Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study in children. The short trial duration should therefore have led to additional downgrading for indirectness according to GRADE. Small trials

2017 Evidence-Based Medicine

63. Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence

factors Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Jessica Agnew-Blais King's College London, London, UK; jessica.agnew-blais{at}kcl.ac.uk Statistics from Altmetric.com ABSTRACT FROM: Roy A, Hechtman L, Arnold LE, et al . Childhood factors affecting persistence and desistence of attention-deficit/hyperactivity disorder symptoms in adulthood: results from the MTA. J Am Acad Child Adolesc Psychiatry 2016;55:937–44. What is already known (...) on this topic While many children with attention-deficit hyperactivity disorder (ADHD) will experience remission of the disorder, 1 a substantial proportion will continue to have ADHD and associated impairments into adolescence and adulthood. 2 Those with persistent ADHD have poorer outcomes later in life in some domains, including more emotional and substance use problems, compared to those whose ADHD remits. 3 Previous studies have identified factors such as childhood ADHD severity, comorbidities 4 and IQ

2017 Evidence-Based Mental Health

64. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

Crescenzo , Samuele Cortese , , Nicoletta Adamo , Luigi Janiri Statistics from Altmetric.com Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neuropsychiatric conditions, with a pooled worldwide prevalence estimated at about 5% in school-aged children and persistence of impairing symptoms in adulthood in up to 65% of cases. The pooled estimated prevalence of ADHD (as categorical diagnosis) in adults is around 2.5%. ADHD is characterised by a persistent and impairing (...) value of combining pharmacological and non-pharmacological treatments. References Faraone SV , Asherson P , Banaschewski T , et al . Attention-deficit/hyperactivity disorder . Moffitt TE , Houts R , Asherson P , et al . Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study . Seixas M , Weiss M , Muller U . Systematic review of national and international guidelines on attention-deficit hyperactivity disorder . Thapar A , Cooper M

2017 Evidence-Based Mental Health

65. Medications for attention deficit hyperactivity disorder (ADHD) in children

Medications for attention deficit hyperactivity disorder (ADHD) in children

2017 DynaMed Plus

67. Attention deficit hyperactivity disorder (ADHD) in children and adolescents

Attention deficit hyperactivity disorder (ADHD) in children and adolescents

2017 DynaMed Plus

69. Vitamin levels in adults with ADHD Full Text available with Trip Pro

Vitamin levels in adults with ADHD Micronutrients containing vitamins are reported to reduce symptom levels in persons with attention-deficit hyperactivity disorder (ADHD), but data on vitamin levels in ADHD are sparse.To examine the relationship between vitamin concentrations, ADHD diagnosis and psychiatric symptoms in young adult ADHD patients and controls.Eight vitamins and the nicotine metabolite cotinine were analysed in serum samples from 133 ADHD patients and 131 controls aged between 18 (...) and 40, who also reported ADHD symptoms and comorbid conditions.Lower concentrations of vitamins B2, B6 and B9 were associated with the ADHD diagnosis, and B2 and B6 also with symptom severity. Smokers had lower levels of vitamins B2 and B9.ADHD patients were overrepresented in the group with low levels of some vitamins, possibly indicative of inadequate dietary intake of these micronutrients in a subgroup of patients. It is important to identify these patients in dietary intervention trials

2016 BJPsych open

70. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Full Text available with Trip Pro

Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD).We identified relevant studies and classified them using American Academy of Neurology criteria.Two Class I studies assessing the ability of EEG theta (...) /beta power ratio and EEG frontal beta power to identify patients with ADHD correctly identified 166 of 185 participants. Both studies evaluated theta/beta power ratio and frontal beta power in suspected ADHD or in syndromes typically included in an ADHD differential diagnosis. A bivariate model combining the diagnostic studies shows that the combination of EEG frontal beta power and theta/beta power ratio has relatively high sensitivity and specificity but is insufficiently accurate.It is unknown

2016 EvidenceUpdates

71. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Full Text available with Trip Pro

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%.To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children.In a 6-week double (...) -blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement tools included the Conners' Parent Rating Scale (CPRS-48), Children's Global Assessment Scale (CGAS), and the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS). Data were analyzed using the Wilcoxon, Mann-Whitney, and Fisher's exact tests in the SPSS 19

2016 Electronic physician Controlled trial quality: uncertain

72. 1-year follow-up of neurofeedback treatment in adolescents with attention-deficit hyperactivity disorder: randomised controlled trial. Full Text available with Trip Pro

1-year follow-up of neurofeedback treatment in adolescents with attention-deficit hyperactivity disorder: randomised controlled trial. Estimates of the effectiveness of neurofeedback as a treatment for attention-deficit hyperactivity disorder (ADHD) are mixed.To investigate the long-term additional effects of neurofeedback (NFB) compared with treatment as usual (TAU) for adolescents with ADHD.Using a multicentre parallel-randomised controlled trial design, 60 adolescents with a DSM-IV-TR (...) ) irrespective of treatment group.Overall, NFB+TAU was as effective as TAU. Given the absence of robust additional effects of neurofeedback in the current study, results do not support the use of theta/SMR neurofeedback as a treatment for adolescents with ADHD and comorbid disorders in clinical practice.None.© The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.

2016 BJPsych open Controlled trial quality: uncertain

73. Personality traits in adults with attention-deficit hyperactivity disorder and their unaffected first-degree relatives Full Text available with Trip Pro

Personality traits in adults with attention-deficit hyperactivity disorder and their unaffected first-degree relatives Attention-deficit hyperactivity disorder (ADHD) shows clear, albeit heterogeneous, cognitive dysfunctions. However, personality traits are not well understood in adults with ADHD, and it is unclear whether they are predisposing factors or phenotypical facets of the condition.To assess whether personality traits of impulsivity, sensation seeking and sensitivity to punishment (...) and reward are predisposing factors for ADHD or aspects of the clinical phenotype.Twenty adults with ADHD, 20 unaffected first-degree relatives and 20 controls completed rating scales assessing traits of impulsivity, sensation seeking and sensitivity to punishment/reward.Compared with relatives and controls, individuals with ADHD showed increased impulsive personality traits, were more susceptible to boredom and presented hypersensitivity to reward but normal sensitivity to punishment.High impulsivity

2016 BJPsych open

74. Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. (Abstract)

; carol.rockhill@seattlechildrens.org. eng Journal Article Comment 2015 10 01 England Evid Based Ment Health 100883413 1362-0347 IM J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):263-74 25791143 Attention Deficit Disorder with Hyperactivity Humans Referral and Consultation Telemedicine PUBLIC HEALTH 2015 06 22 2015 09 15 2015 10 3 6 0 2015 10 3 6 0 2016 8 25 6 0 ppublish 26429338 eb-2015-102151 10.1136/eb-2015-102151 (...) Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. 26429338 2016 08 24 2018 12 02 1468-960X 18 4 2015 Nov Evidence-based mental health Evid Based Ment Health Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. e9 10.1136/eb-2015-102151 Rockhill Carol C Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA

2016 Evidence-Based Mental Health Controlled trial quality: uncertain

75. Omega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis. Full Text available with Trip Pro

Omega-6 to Omega-3 Fatty Acid Ratio in Patients with ADHD: A Meta-Analysis. Omega-3 and omega-6 fatty acids have been shown to be deficient in individuals with attention deficit/hyperactivity disorder compared to controls (Hawkey & Nigg, 2014). Clinical trials of omega-3 and omega-6 supplements as treatment for ADHD have demonstrated minimal efficacy (Bloch & Qawasmi, 2011; Gillies, Sinn, Lad, Leach, & Ross, 2011; Hawkey & Nigg, 2014; Puri & Martins, 2014; Sonuga-Barke et al., 2013). Existing (...) trials have analyzed omega-3 and omega-6 separately although the tissue ratio of these fatty acids (n6/n3) may be more important than absolute levels of either. The objective of this study was to determine the relationship between blood n6/n3 and arachidonic acid to eicosapentaenoic acid (AA/EPA), to ADHD symptoms.A systematic literature review identified original articles measuring blood n6/n3 or AA/EPA ratio in children and youth with ADHD, compared to controls without ADHD. Three databases were

2016 Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Académie canadienne de psychiatrie de l'enfant et de l'adolescent

76. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Full Text available with Trip Pro

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly

2016 BMJ

77. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. (Abstract)

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. Although attention-deficit/hyperactivity disorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents.To review the evidence for pharmacological and psychosocial treatment of ADHD in adolescents.The databases of CINAHL Plus, MEDLINE, PsycINFO, ERIC, and the Cochrane Database (...) Scale (score range, 0 [least symptomatic] to 54 [most symptomatic]), both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 absolute points. The psychosocial treatments combining behavioral, cognitive behavioral, and skills training techniques demonstrated small- to medium-sized improvements (range for mean SD difference in Cohen d, 0.30-0.69) for parent-rated ADHD symptoms, co-occurring emotional or behavioral symptoms, and interpersonal functioning

2016 JAMA

78. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Guanfacine prolonged-release (Intuniv) is a non-stimulant treatment for children and young people with attention deficit hyperactivity disorder (ADHD). In 3 short-term, randomised controlled trials (RCTs) it was more effective than placebo at improving ADHD symptoms, although a beneficial effect on social functioning (...) February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attention deficit hyperactivity disorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD

2016 National Institute for Health and Clinical Excellence - Advice

79. Diagnostic Accuracy of Rating Scales for Attention-Deficit/Hyperactivity Disorder: A Meta-analysis Full Text available with Trip Pro

Diagnostic Accuracy of Rating Scales for Attention-Deficit/Hyperactivity Disorder: A Meta-analysis The Child Behavior Checklist-Attention Problem (CBCL-AP) scale and Conners Rating Scale-Revised (CRS-R) are commonly used behavioral rating scales for diagnosing attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.To evaluate and compare the diagnostic performance of CBCL-AP and CRS-R in diagnosing ADHD in children and adolescents.PubMed, Ovid Medline, and other relevant (...) electronic databases were searched for articles published up to May 2015.We included studies evaluating the diagnostic performance of either CBCL-AP scale or CRS-R for diagnosing ADHD in pediatric populations in comparison with a defined reference standard.Bivariate random effects models were used for pooling and comparing diagnostic performance.We identified and evaluated 14 and 11 articles on CBCL-AP and CRS-R, respectively. The results revealed pooled sensitivities of 0.77, 0.75, 0.72, and 0.83

2016 EvidenceUpdates

80. Pharmacologic Management of Patients with ADHD: Review of Guidelines

. There is limited evidence to support the efficacy or safety of combination therapy for ADHD comprising stimulant and non-stimulant drugs in patients with inadequate clinical response to monotherapy. Tags attention deficit disorder with hyperactivity, attention deficit and disruptive behavior disorders, mental health, ADHD, Attention deficit Files Rapid Response Summary with Critical Appraisal Published : March 18, 2016 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get (...) Pharmacologic Management of Patients with ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines | CADTH.ca Find the information you need Pharmacologic Management of Patients With ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines Published on: March 18, 2016 Project Number: RC0759-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review